Serum CA19-9 levels were measured in 60 diabetic patients and 40 healthy volunteers. Serum CA19-9 concentration was correlated with hemoglobin Al (HbAl) (r=0.4368 P<0.005) and fasting plasma glucose levels (r=0.3410 P<0.01). None of the 40 healthy subjects showed elevated concentrations over 37 units/ml as the upper normal value. The percentage of positive serum CA19-9 levels in poorly controlled patients (fasting plasma glucose > 200 mg/dl or HbAl>13%) and moderately to well controlled patients was 50%and 10%, respectively. No correlation was found between the level of CA19-9and those total cholesterol, and triglycerides, or the duration of diabetes. In patients who had diabetic retinopathy or persistent proteinuria, the CA19-9concentration was significantly elevated when compared with those without these complications. It has been shown that patients with adenocarcinoma of the gastrointestinal tract have high plasma CA19-9 levels and those who have benign disease have normal CA19-9levels. Even though diabetes mellitus is not a malignant disease, serum CA19-9levels were increased in diabetic patients. These results indicate that HbAl and fasting plasma glucose should be examined in patients with high CA19-9 levels. were defined as poorly controlled diabetics.
Fasting blood samples were collected, centrifuged immediately and stored at -20 C. Within 5 days all samples were analyzed. CA19-9 was assayed with a "forward sandwich" radioimmunometric assay using CA19-9á" RIA kits (CENTOCOR, Malvern, PA, USA 
DISCUSSION
We had reported that CA19-9 provides excellent sensitivity for adenocarcinoma of the pancreas, while only a small number of the patients with Benign disease and none of the healthy subjects showed elevated CA19-9 concentrations over 37 units/ml as the upper normal value .
In this study, we found elevated serum concentrations of CA19-9 in poorly controlled diabetic patients, and a correlation between CA19-9 and HbAl or fasting plasma glucose. High serum CA19-9 levels were also found in patients with diabetic retinopathy or persistent proteinuria. Additionally, in these patients, HbAl and fasting plasma glucose levels were elevated.
Therefore, the elevation of CA19-9 may be associated with poor control of diabetes. There are somereports that patients whohave gastrointestinal adenocarcinoma, especially pancreatic cancer, show high plasma CA19-9 levels and those who have benign disease show normal CA19-9 levels3'8~10). Serum concentrations of carcinoembryonic antigen4, which is an oncogenic antigen, was also reported to be increased in diabetic patients, and correlated with fasting plasma glucose levels11~14\
The reason why carcinoembryonic antigen appeared elevated in poorly controlled diabetic patients is still unknown.
In our investigation, serum CA19-9 levels were also elevated in poorly controlled diabetic patients, which leads to speculation that hyperglycemia plays a role in the elevation of these two tumor markers. Consequently 
